INmune Bio to Present at Upcoming Conferences
February 27, 2018 09:30 ET
|
INmune Bio, Inc.
LA JOLLA, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system...
Webinar to Reveal Data Supporting the Use of MuScreen™ for Preclinical Immunotherapeutic Development
February 27, 2018 08:00 ET
|
Crown Bioscience
SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
Tempus Launches Tempus xE, Whole Exome Sequencing to Empower Data-Driven Cancer Care and Research
February 22, 2018 10:30 ET
|
Tempus
CHICAGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data,...
Enhanced MuScreen™ Platform Revolutionizes Preclinical Development of Immunotherapeutics
February 09, 2018 08:00 ET
|
Crown Bioscience
SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
February 06, 2018 08:00 ET
|
Todos Medical Ltd.
REHOVOT, Israel, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Todos Medical, Ltd. Inc. (OTCQB:TOMDF) (www.todosmedical.com), a clinical-stage in-vitro diagnostics company focused on the development of blood...
Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations
February 05, 2018 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...
Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
January 25, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis...
Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 2018
January 23, 2018 08:40 ET
|
Crown Bioscience
SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
INmune Bio presenting at NobleCon14 on January 29th
January 23, 2018 08:30 ET
|
INmune Bio, Inc.
LA JOLLA, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- via Network NewsWire – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune...
Innovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live Webinar
January 17, 2018 08:01 ET
|
Crown Bioscience
SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...